Ian Taras
Obstetrics & Gynecology · Woodland Hills, CANPI 1508873175
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $274,161 of the $359,396 with a category attached, or 76.3%. AbbVie accounts for 79.0% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2019 at $167,366 and has fallen 99.5% since, to $861 in 2025. Among obstetrics & gynecology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 648 payments — averaging $554.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$284K
- Scynexis, Inc.$30K
- AMAG Pharmaceuticals, Inc.$26K
- Therapeuticsmd, Inc.$8K
- Lupin Inc.$6K
- Duchesnay USA Incorporated$2K
- plus $3K from 27 others
What the payments were for
- Consulting fees$37,57510%
- Speaking & faculty fees$274,16176%
- Travel & lodging$31,7819%
- Food & beverage$15,6054%
- Education$2740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 456 | $283,865 |
| Scynexis, Inc. | 5 | $30,207 |
| AMAG Pharmaceuticals, Inc. | 39 | $25,594 |
| Therapeuticsmd, Inc. | 29 | $8,454 |
| Lupin Inc. | 14 | $6,249 |
| Duchesnay USA Incorporated | 8 | $1,748 |
| Novo Nordisk | 14 | $712 |
| Amgen | 4 | $303 |
| Sumitomo Pharma America, Inc. | 10 | $247 |
| Pfizer | 10 | $214 |
| Bayer | 3 | $176 |
| Lilly USA, LLC | 3 | $172 |
| Heartflow, Inc. | 1 | $167 |
| Mayne Pharma Commercial LLC | 5 | $154 |
| Evofem Biosciences, Inc. | 7 | $132 |
| Endo Pharmaceuticals Inc. | 6 | $112 |
| Radius Health, Inc. | 2 | $104 |
| Merck | 2 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $102 |
| Biohaven Pharmaceuticals, Inc. | 4 | $91 |
| Myovant Sciences Inc. | 3 | $83 |
| Exact Sciences | 4 | $80 |
| Millicent US Inc | 2 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $43 |
| Mycovia Pharmaceuticals, Inc. | 1 | $35 |
| Astellas Pharma US Inc | 1 | $32 |
| Avion Pharmaceuticals | 2 | $30 |
| Minerva Surgical, Inc | 1 | $30 |
| Myriad Women's Health, Inc. | 1 | $29 |
| Channel Medsystems, Inc. | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Acella Pharmaceuticals, LLC | 1 | $20 |
| Aspira Women's Health Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$359,396 in reported general payments places this provider in the 95th percentile of 3,784 obstetrics & gynecology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 38 | $36,721 |
| OzempicSemaglutide | 21 | $19,933 |
| ImvexxyEstradiol | 15 | $7,357 |
| Estradiol | 75 | $6,102 |
| Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet | 32 | $2,568 |
| ProgesteroneProgesterone, Micronized | 45 | $2,137 |
| ValacyclovirValacyclovir Hcl | 46 | $1,066 |
| DottiEstradiol | 12 | $709 |
| Celecoxib | 12 | $195 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 15 | $142 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 11 | $87 |
| Fluoxetine Hcl | 13 | $84 |
| Zolpidem Tartrate | 18 | $44 |
| Fluconazole | 13 | $26 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $172 | $36,72138 claims |
| Novo NordiskOzempic | $712 | $19,93321 claims |
| Therapeuticsmd, Inc.Imvexxy | $8,454 | $7,35715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,784 obstetrics & gynecology providers in California.
Other obstetrics & gynecology in Woodland Hills
- Steve YuNorthridge$964K
- Samir HageRedlands$640K
- Malcolm MunroLos Angeles$609K
- Michael KrychmanCosta Mesa$547K
- Anita NelsonTorrance$530K
- Jan SegnitzSan Jose$511K
- Risa KaganBerkeley$497K
- Michael GreenOxnard$424K
- Howard SalvaySanta Cruz$421K
- Marc WinterLaguna Hills$399K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.